Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$3.24
+2.2%
$3.32
$2.71
$4.73
$620.56M1.2955,644 shs660,576 shs
Cerecor Inc. stock logo
CERC
Cerecor
$4.78
-2.4%
$2.60
$1.98
$4.50
$458.92M1.441.27 million shs40,370 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.96
+3.7%
$1.84
$1.33
$2.89
$57.96M1.75413,423 shs124,491 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.79
+1.1%
$14.65
$10.81
$18.06
$291.48M1.1451,326 shs73,525 shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.00%-2.01%-10.20%-3.35%-11.70%
Cerecor Inc. stock logo
CERC
Cerecor
0.00%-3.63%-2.05%-2.45%-60.69%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.00%-1.00%+2.16%+20.38%-2.07%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
0.00%+0.32%+8.32%+28.98%+3.99%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.1441 of 5 stars
3.50.00.00.02.72.50.6
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.5447 of 5 stars
3.51.00.00.02.23.30.6
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.7037 of 5 stars
2.53.00.00.02.52.50.0
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5069.75% Upside
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00971.43% Upside
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$18.3316.11% Upside
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NATR, ABUS, CERC, TLC, and FBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
5/7/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
4/14/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$6.17M100.58N/AN/A$0.51 per share6.35
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M68.50N/AN/A$0.22 per share21.73
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M1.00N/AN/A($0.06) per share-32.67
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$454.36M0.64$1.26 per share12.50$8.71 per share1.81
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$7.70M$0.5329.79N/A2.22%6.98%4.63%8/6/2025 (Estimated)
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A

Latest NATR, ABUS, CERC, TLC, and FBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.02N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/6/2025Q1 2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$0.16$0.25+$0.09$0.25$109.39 million$113.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.04
6.01
6.01
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.41
1.50
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
20.30%
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
5.60%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
90191.53 million152.65 millionOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
85018.46 million17.43 millionOptionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable

Recent News About These Companies

What is the TLC Diet?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.24 +0.07 (+2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$3.33 +0.09 (+2.78%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.96 +0.07 (+3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.91 -0.05 (-2.76%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Nature's Sunshine Products stock logo

Nature's Sunshine Products NASDAQ:NATR

$15.79 +0.17 (+1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$15.78 0.00 (-0.03%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

Taiwan Liposome stock logo

Taiwan Liposome NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.